Dopamine receptor D1-mediated suppression of liver fibrosis via Hippo/Yes-associated protein 1 signaling in levodopa treatment

doi:10.3748/wjg.v31.i34.108617

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 34

This Article

(66)

(80)

(0)

(15)

(2)

(1818)

(3)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Sep 14, 2025; 31(34): 108617
Published online Sep 14, 2025. doi: 10.3748/wjg.v31.i34.108617

Full Size Figure Download Figure

Figure 5 Schematic diagram illustrates the protective mechanism of levodopa on liver fibrosis by inhibiting the Hippo/Yes-associated protein 1 signaling pathway. HSC: Hepatic stellate cell; CCl₄: Carbon tetrachloride; α-SMA: Α-smooth muscle actin; DDC: Dopa decarboxylase, dopamine dopa; DRD1: Dopamine receptor 1; YAP: Yes-associated protein 1.

Citation: Wang HY, Qi MM, Zhang K, Zhu YZ, Zhang J. Dopamine receptor D1-mediated suppression of liver fibrosis via Hippo/Yes-associated protein 1 signaling in levodopa treatment. World J Gastroenterol 2025; 31(34): 108617
URL: https://www.wjgnet.com/1007-9327/full/v31/i34/108617.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i34.108617

Wang HY, Qi MM, Zhang K, Zhu YZ, Zhang J. Dopamine receptor D1-mediated suppression of liver fibrosis via Hippo/Yes-associated protein 1 signaling in levodopa treatment. World J Gastroenterol 2025; 31(34): 108617 [PMID: 40937451 DOI: 10.3748/wjg.v31.i34.108617]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.